Lenzilumab  (Synonyms: KB 003)

Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies^[1][2].

Human IgG1(K214R) kappa

Human IgG1 (K214R) kappa, Isotype Control

Human

CSF2/GM-CSF

Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1437  [NCBI]

P04141

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.72 kDa

1229575-09-0

Liquid

Colorless to light yellow

[Lenzilumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded Lenzilumab on AHC2 biosensor, can bind GM-CSF Protein, Human (His, HY-P7016C) with an affinity constant of 5.364E-10 M as determined in BLI assay.
• 
  Lenzilumab(HY-P99207) neutralizes Recombinant Human GM-CSF (HY-P7016A) induced proliferation in the TF-1 human erythroleukemic cell line. The Neutralization Dose (ND50) for this effect is 0.02545μg/mL in the presence of 0.5 ng/mL Recombinant Human GM-CSF.

• [1]. Rosalie M Sterner, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14;133(7):697-709.  [Content Brief]

  [2]. Zelalem Temesgen, et al. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov;95(11):2382-2394.  [Content Brief]